In other words, if the invasive or aggressive molecular characteristics can be determined in FSH-positive NFPAs, then in the future when one meet this type of FSH-positive NFPA patient and the corresponding molecular changes, whatever the tumor size and already damage to tumor-surrounding structures, then this type of NFPA patients should be considered for personalized, and extra treatment strategy after neurosurgery. Here, BRD2 is linked to neoplasm.